小儿智力糖浆治疗注意缺陷多动障碍并睡眠障碍临床评价  

Clinical Observation of Xiao’er Zhili Syrup in the Treatment of Attention Deficit Hyperactivity Disorder with Sleep Disorder in Children

作　　者：吴启富[1] 赵宁[1] 匡彪 

机构地区：[1]华蓥市妇幼保健院儿科,四川华蓥

出　　处：《亚洲儿科病例研究》2017年第1期1-6,共6页Asian Case Reports in Pediatrics

摘　　要：目的:观察小儿智力糖浆治疗注意缺陷多动障碍并睡眠障碍的疗效和安全性。方法:选择90例注意缺陷多动障碍并睡眠障碍患儿,随机分为治疗组与对照组,治疗组口服小儿智力糖浆,对照组服哌甲酯,疗程12周。治疗结束后采用ADHD父母评定量表(ADHD-IV Rating Scale-Parent Version, ADHDRS-IV-P)、Conners父母症状问卷(Parent Symptom Questionnaire, PSQ )和儿童睡眠状况调查问卷(Children Sleep Habit Questionnaire, CSHQ)进行疗效评定。结果:治疗组脱落5例,对照组脱落5例。两组治疗后ADHDRS-IV-P、PSQ和CSHQ评分比较差异有统计学意义(P <0.05)。两组患儿在治疗过程中均未发现严重的药物不良反应。结论:小儿智力糖浆治疗注意缺陷多动障碍并睡眠障碍疗效显著,不良反应少,值得临床推广。Objective: To observe the efficacy and safety of Xiao’er zhili syrup in the treatment of attention defi-cit hyperactivity disorder (ADHD) with sleep disorder in children. Methods: 90 cases of ADHD with sleep disorder were separated randomly into treatment group and control group (45 cases for each). The treatment group was given Xiao’er zhili syrup and the control group was given methylpheni-date. The treatment course was designed to be 12 weeks. The efficacy was assessed with the ADHD-IV Rating Scale-Parent Version (ADHDRS-IV-P), Parent Symptom Questionnaire (PSQ) and Children Sleep Habit Questionnaire (CSHQ). Results: 5 patients fell off in the treatment group and 5 fell off in the control group. The scores of ADHDRS-IV-P, PSQ and CSHQ after treatment in treatment group were lower than that in control group. The difference was statistically significant .

关 键 词：小儿智力糖浆 注意缺陷多动障碍 睡眠障碍 

分 类 号：R74[医药卫生—神经病学与精神病学]